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Abstract
Background: Immunological and genetic findings implicate Th17 effector cytokines in the pathogenesis of
inflammatory bowel disease (IBD). Expression of Th17 pathway-associated genes is mainly studied in colonic
disease. The present study assessed the mRNA expression levels of Th17 effector cytokines (IL17A, IL17F, IL21, IL22
and IL26) and genes involved in differentiation (IL6, IL1B, TGFB1, IL23A and STAT3) and recruitment of Th17 cells
(CCR6 and CCL20) by quantitative real-time PCR analysis of colonic and ileal biopsies from 22 healthy control
subjects, 26 patients with Crohn’s disease (CD) and 12 patients with ulcerative colitis (UC). Inflammation was
quantified by measuring expression of the inflammatory mediators IL8 and TNF.
Results: Evaluation of mRNA expression levels in colonic and ileal control samples revealed that TNF, TGFB1, STAT3
and CCR6 were expressed at higher levels in the ileum than in the colon. Expression of all the Th17 pathway-
associated genes was increased in inflamed colonic samples. The increased expression of these genes was
predominantly observed in samples from UC patients and was associated with more intense inflammation.
Although increased expression of IL17A, IL17F, IL21 and IL26 was detected in inflamed ileal samples, expression of
the indispensable Th17 cell differentiation factors TGFB1 and IL23A, the signaling molecule STAT3 and the Th17
recruitment factors CCR6 and CCL20 were unchanged.
Conclusions: Our findings suggest that immune regulation is different in colonic and ileal disease, which might
have important consequences for therapeutic intervention.
Background
The location and pattern of inflammation in inflamma-
tory bowel disease (IBD) are variable. Whereas ulcera-
tive colitis (UC) is limited to the colon with a sharp
delineation between the involved and non-involved
mucosa, Crohn’s disease (CD) can affect any part of the
gastrointestinal tract and is associated with patchy dis-
tribution of mucosal lesions. Ileal localization occurs in
about 80% of CD patients, and about 30% of CD
patients have isolated ileal disease. Although it is gener-
ally accepted that IBD develops as a result of an altered
immune response to luminal content in a genetically
susceptible host, the mechanism by which the site of
disease is selected remains unknown. Important differ-
ences in function, architecture and bacterial distribution
between the ileum and colon have been described.
Peyer’s patches, which consist of aggregated lymphoid
tissue and play a central role in the induction of muco-
sal immune responses, are a hallmark of the terminal
ileum. Increased numbers of mucosa-associated E. coli
are observed in IBD, and adherent invasive E. coli
(AIEC) strains were highly associated with the ileal
mucosa in CD patients. Moreover, the reduced number
of goblet cells in the ileum results in decreased mucus
secretion and increased contact between the mucosa
and luminal content [1-3].
Several subsets of T helper (Th) cells contribute to
defensive responses at inflammatory sites [4]. Dendritic
cell-derived cytokines skew the differentiation of naïve
CD4+ T cells into Th1, Th2, Th17 or regulatory T cell
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(Treg) subsets. For many years, CD was believed to be
mediated by Th1 cytokines, while UC was believed to be
mediated by Th2 cytokines; however, recent data have
implicated Th17 cells in the pathogenesis of IBD [5-9].
The invasion of extracellular bacteria into the intestinal
mucosa triggers the expression of IL-23A, driving Th17
cells to release IL-17A, IL-17F, IL-21, IL-22 and IL-26,
which in turn exert a number of proinflammatory effects
on intestinal epithelial cells, endothelial cells, macro-
phages and fibroblasts [10]. In addition to their proin-
flammatory functions, IL-17A, IL-17F and IL-22 have
been reported to induce increased expression of epithe-
lial barrier protective genes such as defensins, mucins,
tight junction proteins and lipopolysaccharide-binding
proteins [11-14].
The differentiation of Th17 cells depends on the activa-
tion of janus kinase 2 (JAK2), signal transducer and activa-
tor of transcription 3 (STAT3) and the transcription factor
RAR-related organ receptor C2 (RORC2) and is regulated
by a combination of cytokines, including IL-6, IL-1B (IL-
1b), TGFB1 (TGFb), IL-23A, and the autocrine activity of
IL-21 [4,15-20]. Chemokine (C-C motif) receptor 6
(CCR6) which is expressed on the surface of Th17 cells,
contributes to their recruitment to chemokine (C-C motif)
ligand 20 (CCL20) produced at the inflamed mucosa [21].
The important role of Th17 cells in the pathogenesis
of IBD is also supported by genome-wide association
studies, which have demonstrated that CCR6, STAT3,
JAK2, IL23R and IL12B are CD susceptibility genes
[22-24]. Interestingly, single nucleotide polymorphisms
(SNPs) within IL23R, IL12B, STAT3, JAK2, the IL22/
IL26 and the IL2/IL21 gene cluster have also been found
to be associated with UC [22,24-27].
Although the expression of Th17-related genes has
been studied previously, most studies included only
colonic samples and were focused on a limited number
of genes. Increased expression of IL17A, IL17F, IL22,
IL26, IL21, CCL20 and CCR6 has been found in
inflamed colonic tissues of IBD patients [4,14,28-33].
In only one study, IL17A and IL23 were mildly increased
in active ileal CD samples [34].
To examine the possible differences in the expression
levels of genes involved in the Th17 pathway, we
assessed the mRNA levels of the Th17 effector cytokines
and genes involved in the differentiation and recruit-
ment of Th17 cells in both colonic and ileal biopsies of
healthy controls, UC patients and CD patients.
Results
The mRNA expression levels of inflammatory cytokines
and Th17-related genes in colonic and ileal samples of
healthy controls
The expression level of the proinflammatory cytokine
IL8 was equal in colonic and ileal controls, while the
expression level of TNF (TNFa) was slightly higher in
ileal control samples than in colonic control samples
(P = 0.037) (Figure 1A).
The expression levels of the Th17 effector cytokines
IL17A, IL17F, IL21, IL22 and IL26 were comparable
between colonic and ileal control samples (Figure 1B);
however, the expression of these cytokines in each indi-
vidual sample was not consistent. In one ileal sample
and none of the colonic samples, all five cytokines were
expressed. In one colonic sample and four ileal samples,
three to four cytokines were expressed, while in eight
colonic samples and seven ileal samples, one to two
cytokines were expressed. In four colonic samples and
three ileal samples, none of the five cytokines were
detected.
We next examined the expression of genes involved in
the differentiation of Th17 cells. TGFb (P = 0.0005) and
STAT3 (P = 0.007) were expressed at higher levels in
ileal control samples than in colonic control samples,
while IL6, IL1b and IL23A expression levels were similar
in colonic and ileal control samples (Figure 1C).
Expression of genes involved in the recruitment of
Th17 cells was also assessed. CCR6 expression was
higher in ileal control samples than in colonic control
samples (P = 0.0008), while CCL20 expression was simi-
lar between colonic and ileal controls (Figure 1D).
The mRNA expression levels of inflammatory mediators in
inflamed colonic and ileal samples of IBD patients
Although all samples were taken from endoscopically
inflamed mucosa, we quantified inflammation by mea-
suring the expression of the proinflammatory cytokines
IL8 and TNFa. The expression level of IL8 has been
shown to be associated with the grade of inflammation
[35,36]. IL8 was strongly induced in inflamed colonic
samples from UC (P < 0.0001) and CD patients (P =
0.0004) and in inflamed ileal samples from CD patients
(P < 0.0001) (Figure 2A). The expression level of IL8
was significantly higher in UC samples than in colonic
CD samples (P = 0.017). Expression of TNFa was only
significantly increased in UC samples (P = 0.0002); how-
ever, a tendency for increase was observed in ileal CD
samples (P = 0.052) (Figure 2A). Expression levels of
TNFa were significantly higher in UC samples than in
colonic CD samples (P = 0.028).
The mRNA expression levels of Th17 effector cytokines in
inflamed colonic and ileal samples of IBD patients
In UC samples, IL17A (P = 0.0002), IL21 (P = 0.0021),
IL22 (P = 0.0003) and IL26 (P = 0.0017) were strongly
induced, and IL17F (P = 0.046) was weakly induced,
while in colonic CD samples, IL17A (P = 0.0084) and
IL22 (P = 0.001) were strongly induced, and IL21 (P =
0.047), IL26 (P = 0.048) and IL17F (P = 0.011) were
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Figure 1 mRNA expression levels of proinflammatory and Th17-pathway-associated genes in colon and ileum of healthy controls. The
relative transcription levels are determined by SYBR Green qPCR using the geometric mean of GAPDH, HPRT and SDHA as an endogenous
control in colonic and ileal samples from healthy controls. The data are expressed as geometric means. The geometric mean of the colonic
controls was set as 1. Data are presented on a log scale. (a) proinflammatory cytokines, (b) Th17 effector cytokines, (c) Th17 differentiation
factors, (d) Th17 recruitment factors. *P < 0.05, **P < 0.01, ***P < 0.001
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Figure 2 mRNA expression levels of proinflammatory and Th17-pathway-associated genes in inflamed colonic and ileal samples of
IBD patients. Fold changes in transcription levels are determined by SYBR Green qPCR using the geometric mean of GAPDH, HPRT and SDHA as
an endogenous control in inflamed colonic UC, colonic CD and ileal CD samples. The fold changes shown are relative to control samples. The
data are presented as box plots with medians and interquartile ranges. (a) proinflammatory cytokines, (b) Th17 effector cytokines, (c) Th17
differentiation factors, (d) Th17 recruitment factors. *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.0001
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weakly induced (Figure 2B). In ileal CD samples, IL22 (P
= 0.0015) was strongly induced, while IL17A (P =
0.013), IL26 (P = 0.029) and IL17F (P = 0.019) were
weakly induced, and expression levels of IL21 were simi-
lar to those in ileal controls. Furthermore, in the colon,
expression levels of IL17A (P = 0.005) and IL21 (P =
0.036) were significantly higher in UC samples than in
CD samples. In CD samples, expression of IL21 (P =
0.0097) was significantly higher in the colon than in the
ileum.
The mRNA expression levels of genes involved in the
differentiation of Th17 cells in inflamed colonic and ileal
samples of IBD patients
IL1b (UC, P≤0.0001; CD, P = 0.0009), IL6 (UC,
P≤0.0001; CD, P = 0.0007), TGFb (UC, P = 0.0002; CD,
P = 0.0001) and IL23A (UC, P = 0.0006; CD, P = 0.003)
were strongly induced in both UC and colonic CD (Fig-
ure 2C). STAT3 was only slightly induced in colonic CD
(P = 0.015) and UC (P = 0.018). Although a strong
induction of the Th17 differentiation factor IL1b (P =
0.0007) and a weak induction of IL6 (P = 0.015) were
observed in ileal samples, TGFb, IL23A and STAT3
were not induced. In the colon, IL23A was expressed at
higher levels in UC samples than in CD samples (P =
0.027). In CD samples, TGFb (P = 0.0008) and IL23A (P
= 0.010) were expressed at higher levels in the colon
than in the ileum.
The mRNA expression levels of genes involved in the
recruitment of Th17 cells in inflamed colonic and ileal
samples of IBD patients
Expression levels of both CCR6 (UC, P = 0.0004; CD,
P = 0.011) and CCL20 (UC; P = 0.0003, CD; P = 0.0009)
were significantly increased in colonic CD and UC sam-
ples but not in ileal CD samples (Figure 2D).
The mRNA expression levels of the master transcription
factor RORC in inflamed colonic and ileal samples of IBD
patients
Two sets of primers for RORC were developed. The
RORC primers detect both the full-length transcript and
the shorter T cell-specific isoform, while the RORC1 pri-
mers detect only the full-length transcript. A strong cor-
relation was found between RORC1 and RORC
expression levels (R = 0.776, P < 0.001). When compar-
ing the RORC1 and RORC levels between healthy con-
trols and UC and CD patients, higher significance levels
were achieved using the primer detecting both tran-
scripts. This suggests a stronger role for the T cell-
specific RORC2 isoform.
In colonic samples from CD and UC patients, RORC
mRNA expression levels were comparable to those in
healthy controls, while in ileal CD samples, expression
levels of RORC were lower than those in control sam-
ples (P = 0.0019) (Figure 3).
Discussion
A growing body of human studies and studies in mouse
models has shown that Th17 effector cytokines promote
chronic intestinal inflammation through the induction
of multiple proinflammatory mediators. The role of
Th17 cells has predominantly been studied in CD; these
cells have rarely been studied in UC and have never
been studied in healthy controls. Although it is generally
accepted that IBD develops as a result of an altered
immune response to luminal content in a genetically
susceptible host, the factors influencing the selection of
the disease site remain unknown. At present, even the
mechanisms controlling development of ileitis and/or
colitis in transgenic or gene-targeted mouse models are
unclear.
In the present screening study the mRNA expression
signatures of Th17 pathway-associated genes were eval-
uated in colonic and ileal samples of healthy controls,
UC and CD patients. We first compared the expression
levels in healthy colons to those in healthy ilea. Evalua-
tion of the Th17 effector cytokines revealed no signifi-
cant differences in expression levels between the colon
and the ileum. Notably, these cytokines were not detect-
able in the majority of control samples, although expres-
sion was more frequently observed in ileal samples than
in colonic samples. In addition, the expression of one
Th17 effector cytokine was not necessarily linked to the
expression of the other effector cytokines in a single
mucosal specimen. The relative stasis of luminal content
in the terminal ileum supports our observation that
Th17 effector cytokines were more often present in the
ileum than in the colon because IL-17A, IL-17F and IL-
22 enhance the production of antimicrobial peptides,
which protect the intestinal mucosa against bacterial
invasion [11-14]. The diversity of bacteria present
among individuals might explain why not all individuals
express Th17 effector cytokines.
Recently, a subset of CD4+ T cells that provide help to
B cells for antibody production in germinal centers
(GC), termed follicular helper T cells (Tfh), were identi-
fied [37,38]. Tfh cells produce IL-21, which is necessary
for GC formation. The increased number of ileal con-
trols expressing IL21 could reflect the presence of
Peyer’s patches in the terminal ileum, where B lympho-
cytes predominate in the GC. The associated increased
ileal expression of the downstream signaling molecule
STAT3 supports this assumption.
CCR6, which is present not only on Th17 cells but
also on Treg cells, B cells, neutrophils and immature
dendritic cells, plays a critical role in the migration of
these cells to its ligand CCL20, which is produced at
Bogaert et al. BMC Immunology 2010, 11:61
http://www.biomedcentral.com/1471-2172/11/61
Page 5 of 11
inflammatory sites [14,20,33]. CCR6-positive cells have
been detected in lymphoid organs like Peyer’s patches
and isolated lymphoid follicles and seem to be more
common in the ileum than in the colon. TGFb was
shown to be the main factor for induction of CCR6
mRNA expression in Th17 cells and dendritic cells
[39,40]. In our study, the increased expression of CCR6
in ileal controls was correlated with increased ileal
TGFb (r = 0.785, P = 0.0003).
The increased expression of the proinflammatory cyto-
kine IL8 in the inflamed colonic and ileal IBD samples
confirmed the endoscopic inflammatory state of our
samples. The relationship between the expression of
proinflammatory cytokines and the grade of inflamma-
tion or disease activity index has been described before
and is supported by our observation that IL8 expression
levels in samples from patients in remission are similar
to those of healthy controls (data not shown) [35,36].
TNFa is less useful as parameter of inflammation
because reports about its expression and secretion in
inflamed samples are contradictory [41-43]. In support
of this view, expression of TNFa was increased in UC
patients and not increased in CD patients.
Except for ileal IL21, significant induction of all Th17
effector cytokines was observed in inflamed colonic and
ileal IBD samples. Moreover, induction of IL17A and
IL21 was significantly more pronounced in UC than in
colonic CD, and this induction was associated with
more intense inflammation as defined by increased
induction of IL8. In contrast, this association was not
found in ileal CD where only marginal induction of
Th17 cytokines was detected in ileal CD samples with
IL8 expression levels similar to those observed in UC
samples. Marked induction of IL1b, IL6, TGFb and
IL23A, genes involved in the differentiation of Th17
cells, was observed in colonic inflammation. The down-
stream signaling molecule STAT3 was only moderately
increased in colonic samples. In ileal CD samples,
except for a strong induction of IL1b, only a weak
induction of IL6 and no increase in TGFb, IL23A and
STAT3 was detected. In parallel, significant increases in
CCR6 and CCL20, genes involved in the recruitment of
Th17 cells, were only observed in colonic samples, sup-
porting a less pronounced infiltration of Th17 cells in
ileal inflammation.
The observed increase in expression levels of IL17A,
IL17F, IL22 and IL26 and the downstream proinflamma-
tory cytokines IL6 and IL1b in the inflamed ileum could
originate from cells other than Th17 cells. Lymphoid
tissue inducer-like cells, which are important in the
development of lymphoid organs, are an innate source
of IL-17A and IL-22 [44]. Paneth cells, which are com-
mon in the ileum, also express IL-17A [45]. Natural
killer cells, natural killer T cells and a newly identified T
helper cell, Th22 cells, which are involved in inflamma-
tory skin disorders, are sources of IL-22 [46]. Impor-
tantly, IL-17A, IL-17F and IL-22 mediate protective
effects through the induction of defensins [11-14].
Although mRNA expression levels are not the optimal
way to study the activity of transcription factors, the sig-
nificantly reduced expression of ileal RORC support a
defect in the Th17 pathway in ileal disease.
We should consider the fact that gene expression
could be affected by the use of anti-inflammatory drugs.
Although 42% of the included patients were on medica-
tion, statistical analysis did not show an effect.
Given that SNPs within CCR6, STAT3, JAK2, IL23R,
IL12B, the IL22/IL26 and the IL2/IL21 gene cluster have
Figure 3 mRNA expression levels of RORC in inflamed colonic and ileal samples of IBD patients. The relative transcription levels of RORC
are determined by SYBR Green qPCR using the geometric mean of GAPDH, HPRT and SDHA as an endogenous control in (a) colonic and (b) ileal
samples from healthy controls, UC patients and CD patients. The geometric mean of the control samples was set as 1. Data are presented on a
log scale. **P < 0.01
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been found to be associated with CD and or UC, we
should take in mind the influence of these SNPs on
Th17 cytokine profiles. Recently, response to anti-TNF
therapy was demonstrated to be modulated by IL23R
variants, linking Th17 function to biologicals [47].
Twenty-two percent of the samples in this study were
included in the GWAS of Barrett and thus genotyped
for CCR6, STAT3, JAK2, IL23R and IL12B [23]. Unfortu-
nately, due to a low frequency of patients heterozygous
or homozygous for the different risk alleles, such com-
parisons were not conclusive [47].
A lot of factors inherent to the heterogeneous nature
of biopsies may influence RNA levels. Although we have
to be cautious with the extrapolation of mRNA expres-
sion data to functional immunological conclusions, bio-
logical replicates and the previously demonstrated
association between RNA and protein levels of most
genes included in this study contribute to reliable
conclusions.
Conclusions
In conclusion, this study demonstrated important differ-
ences in the expression of Th17-associated genes in
colonic and ileal disease. Inflammation of the colon of
both CD and UC patients is clearly associated with
increased expression levels of Th17 effector cytokines
and genes involved in the differentiation, amplification
and recruitment of Th17 cells, whereas in the inflamed
ileum, essential factors for differentiation and recruit-
ment of Th17 cells are missing. The differential expres-
sion of Th17-related genes between the colon and ileum
could reflect different immune regulation in the colon
and ileum, suggesting different therapeutic approaches
for CD patients with colonic versus ileal disease. Future
clinical trials of agents blocking Th17-related genes
should take into account the disease location in CD
patients. In addition, the difference in expression pro-
files between the colon and ileum also provide the
potential of identifying diagnostic biomarkers.
Methods
Patients and samples
A total of 72 macrodissected intestinal tissue samples
from 22 healthy controls, 12 UC patients and 26 CD
patients were obtained during colonoscopy with a Sin-
gle-Use Biopsy Forceps Radial Jaw3 (Boston Scientific,
El Coyol, Costa Rica) (Table 1). The size of a biopsy
specimen was usually between 2-4 mm2 with an esti-
mated average weight of 6.4 mg. UC and CD patients
were diagnosed based on clinical, endoscopic and histo-
logical criteria. Patients characteristics, medication
intake and the Montreal classification which gives an
overview of the subclassification of IBD patients is
shown in Table 1[48]. Mucosal inflammation was
defined as the presence of endoscopic signs of disease
activity. Samples from healthy controls were taken from
the ileum and sigmoid of patients who underwent colo-
noscopy to screen for cancer or polyps. All biopsies col-
lected during colonoscopy were immediately stored in
RNALater (Ambion, Cambridgeshire, UK) at -80°C. The
study was in accordance with the guidelines of the Hel-
sinki Declaration (1964 and amended in 1975, 1983,
1989, 1996 and 2000) of the World Medical Association.
Informed consent was obtained from all patients, and
the protocol was approved by the local Ethics Commit-
tee of Ghent University Hospital (EC UZG 2004/242).
RNA extraction, cDNA synthesis and amplification
Total RNA was extracted from 2-3 pooled mucosal sam-
ples using an RNeasy Mini Kit (Qiagen, Westburg BV,
The Netherlands) with on-column DNAse treatment
(Qiagen). Needle homogenization was performed. The
total RNA was quantified using spectrophotometry
(Nanodrop; Thermo Scientific, Wilmington, USA) and
ranged from 150 ng to 16.8 μg with an average of 5.9 μg
total RNA. The quality of the RNA, expressed as RNA
quality indicator (RQI), was checked by automated elec-
trophoresis (Experion, Bio-Rad, Hercules, California) and
ranged from 7.4 to 10 with an average of 8.6. Starting
from 20 ng of total RNA, the WT-Ovation RNA Amplifi-
cation System (Nugen Technologies Inc., San Carlos,
USA) was used to the letter of the manufacturer’s
instructions, generating approximately 6 μg of cDNA.
First strand cDNA is prepared from total RNA using
both oligo-dT and random hexamer primers and reverse
transcriptase. After the generation of double strand
cDNA, a DNA amplification step developed by NuGEN
was performed. The cDNA was diluted to 50 μl.
Quantitative real-time PCR
PCR amplification reactions were carried out in a total
volume of 8 μl containing 2× SYBR Green I Master Mix
(Eurogentec, Seraing, Belgium), 3 μl 1/100 cDNA (~3.75
ng) and 250 nM forward and reverse primers (BioLegio,
Nijmegen, The Netherlands). All reactions were per-
formed in 384-well plates (LightCycler 480 Multiwell
Plates 384, white and LightCycler 480 Sealing Foils from
Roche) on the CFX384 real-time PCR detection system
(Bio-Rad, Hercules, California), followed by a regression
Cq value determination method. Cycling conditions were
as follows: 95°C for 10 min followed by 45 cycles of 95°C
for 10 s and 60°C for 30 s, followed by a dissociation
curve analysis from 60 to 95°C. Because instrument and
liquid handling variations were shown to be minimal
using the Tecan Freedom Evo robot for pippeting (< 6%
CV in 0.5 μl and <3% CV in 2 μl), and a large number of
biological replicates were used, no PCR replicates were
carried out. Primers containing neither SNPs nor
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Table 1 Characteristics of control subjects and patients
Colonic biopsies Ileal biopsies
Healthy controls UC
inflamed
CD
inflamed
Healthy controls CD
inflamed
N (Biopsy specimens) 13 12 15 16 16
Gender (male/female) 4/9 9/3 10/5 7/9 10/6
Age, yrs (mean, range) 55
(22-69)
38
(20-79)
30
(13-64)
51
(27-69)
32
(8-59)
Age at diagnosis
(A1, A2, A3) 1/8/3 4/9/2 5/8/3
Maximal location of disease
(L1, L2, L3) 0/3/12 5/0/11
(E1, E2, E3) 0/8/4
Maximal disease behavior
(B1, B2, B3) 8/5/2(6P) 9/5/2(5P)
Medication
No 13 2 8 16 8
5-aminosalicylates 3 1 4
Corticosteroids 0 1 1
Immunosuppressives 2 3 3
Biologicals 0 1 0
Combination 5 1 0
Age at diagnosis; A1: 0-16 yrs, A2: 16-40 yrs, A3: >40 yrs. Maximal location of disease; CD; L1: solely ileal disease, L2: solely colonic disease, L3: ileal and colonic
disease, UC; E1: ulcerative proctitis, E2: left-sided UC, E3: pancolitis. Maximal disease behavior; B1: non-stricturing, non-penetrating, B2: stricturing, B3: penetrating,
(XP): number of patients when concomitant perianal disease was present.
Table 2 Sequences and exon locations of qPCR primers, amplicon lengths, PCR efficiencies and correlation coefficients
Gene
Symbol
Reference
sequence
Forward primer location Reverse primer location Amplicon
length (bp)
PCR
efficiency
(%)
R2
GAPDH NM_002046 TGCACCACCAACTGCTTA C Ex7 GGCATGGACTGTGGTCATGAG Ex7-8 87 109 0,99
SDHA NM_004168 TGGGAACAAGAGGGCATCTG Ex2 CCACCACTGCATCAAATTCATG Ex3 86 104 0,9914
HPRT NM_000194 TGACACTGGCAAAACAATGCA Ex5-6 GGTCCTTTTCACCAGCAAGCT Ex6 94 110 0,9985
IL8 NM_000584 GAATGGGTTTGCTAGAATGTGATA Ex4 CAGACTAGGGTTGCCAGATTTAAC Ex4 129 99 0,9995
TNF NM_000594 CCTGCCCCAATCCCTTTATT Ex4 CCCTAAGCCCCCAATTCTCT Ex4 80 88 0,9991
IL17A NM_002190 CCATAGTGAAGGCAGGAATC Ex3 CGGTTATGGATGTTCAGGTT Ex3 108 98 0,998
IL17F NM_052872 AGCGCAACATGACAGTGAAG Ex1 GTGTAATTCCAGGGGGAGGT Ex2 105 89 0,993
IL21 NM_021803 ACTTGGTCCCTGAATTTCTGC Ex1-2 TTTGTGGAAGGTGGTTTCCTC Ex3 169 92 0,9891
IL22 NM_020525 TTCCAGCAGCCCTATATCACC Ex1 GCTCACTCATACTGACTCCGTG Ex2-3 125 102 0,9937
IL26 NM_018402 ATCAAAGCAGCATGGCTCAAA Ex1 GCAGTTGACCAAAAACGTCTTCC Ex3 154 104 0,9894
IL1B NM_000576 CACGATGCACCTGTACGATCA Ex5 GTTGCTCCATATCCTGTCCCT Ex5 121 90 0,9991
IL6 NM_000600 ATTCTGCGCAGCTTTAAGGA Ex5 AACAACAATCTGAGGTGCCC Ex5 119 104 0,9956
TGFB1 NM_0006600 GGCCAGATCCTGTCCAAGC Ex1 GTGGGTTTCCACCATTAGCAC Ex1 201 93 0,9872
IL23A NM_016584 TTCTGCTTGCAAAGGATCCA Ex3 AATATCCGATCCTAGCAGCTTCTC Ex3 64 106 0,9957
STAT3 NM_139276 GATCCAGTCCGTGGAACCAT Ex21 ATAGCCCATGATGATTTCAGCAA Ex21 74 106 1
CCR6 NM_031409 GTGCAAGTTGCTAAAAGGCATC Ex3 CGAATGACTTAGTCGCCTGT Ex3 112 89 1
CCL20 NM_004591 TGCTGTACCAAGAGTTTGCTC Ex1 CGCACACAGACAACTTTTTCTTT Ex3 220 98 0,9914
RORC NM_005060 GTAACGCGGCCTACTCCTG Ex4 GTCTTGACCACTGGTTCCTGT Ex5 227 102 0,9944
RORC
(RORC1)
NM_005060 GCAAAGAAGACCCACACCTC Ex2-3 GCACCCCTCACAGGTGATAA Ex3 102 112 0,9843
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secondary structures were designed for Glyceraldehyde
3-phosphate dehydrogenase (GAPDH), Succinate dehy-
drogenase complex subunit A (SDHA), Hypoxanthine-
guanine phosphoribosyltransferase (HPRT), IL8,
TNF, TGFB1, IL1B, IL6, IL23A, CCR6, STAT3, IL17A,
IL17F, IL21, IL22, IL26, CCL20 and RORC (Table 2). For
RORC, two sets of primers were designed, RORC, which
detects the mRNA levels of both isoforms, and RORC1
which detects only the full-length transcript. BLAST
searches confirmed that only the target genes were 100%
covered. A 6 point 4-fold standard dilution series (highest
concentration; 32 ng/μl) of a cDNA mixture of all sam-
ples included in the study diluted in 5 ng/μl tRNA
(Roche) was used to test the PCR efficiency of the pri-
mers. The dynamic range had to cover at least 3 orders of
dilution. Only primers with an efficiency between 88%
and 112% were retained (Table 2). Correlation coeffi-
cients of the targets were between 0.9843<R2 < 1, with a
mean of 0.9942 (Table 2). The PCR efficiency for each
gene was calculated according to the equation E = 10 (-1/
slope). Each sample has been revised for a melting-curve
with a single sharp peak with a high correlation between
the observed and the expected Tm (mean variation of
0.9°C). Samples with other patterns than a single sharp
peak at the expected Tm, defined as multiple peaks, a sin-
gle broader peak or a shoulder peak, were omitted. Cq
values of samples with flattened melting-curves were set
as 45. An amplification signal in the no template control
(NTC) was ignored as long as the difference in Cq value
between the NTC and the highest Cq >5. Although the
pre-amplification method of NuGEN does not amplify
genomic DNA, possible gDNA contamination was
assessed using intronic primers. We confirmed that
gDNA was undetectable in a dilution of up to 32 ng/μl
cDNA [49]. The mRNA expression level of each gene was
determined in Excel by using the comparative 2-(delta
delta Cq) method and normalized to the geometric mean
of the stably-expressed reference genes GAPDH, SDHA
and HPRT as determined by geNorm [50].
According to the MIQE guidelines, the minimum
information for publication of quantitative real-time
PCR experiments was provided [51].
Statistical analysis
Statistical differences were assessed using a non-parame-
trical Mann-Whitney U test (two tailed probabilities).
The correlations were analyzed with Spearman’s correla-
tion coefficient. P-values less than 0.05 were considered
significant. Statistical analysis was performed using SPSS
software 11.5 (SPSS, Chicago, USA).
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